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Abstract
Meningeal solitary fibrous tumor (SFT)/hemangiopericytoma (HPC) is a rare tumor with propensity for recurrence and 
metastasis. Although multiple classification schemes have been proposed, optimal risk stratification remains unclear, and 
the prognostic impact of fusion status is uncertain. We compared the 2016 WHO CNS tumor grading scheme (CNS-G), a 
three-tier system based on histopathologic phenotype and mitotic count, to the 2013 WHO soft-tissue counterpart (ST-G), 
a two-tier system based on mitotic count alone, in a cohort of 133 patients [59 female, 74 male; mean age 54 years (range 
20–87)] with meningeal SFT/HPC. Tumors were pathologically confirmed through review of the first tumor resection (n = 97), 
local recurrence (n = 35), or distant metastasis (n = 1). A STAT6 immunostain showed nuclear expression in 132 cases. 
NAB2–STAT6 fusion was detected in 99 of 111 successfully tested tumors (89%) including the single STAT6 immunonega-
tive tumor. Tumors were classified by CNS-G as grade 1 (n = 43), 2 (n = 41), or 3 (n = 49), and by ST-G as SFT (n = 84) 
or malignant SFT (n = 49). Necrosis was present in 16 cases (12%). On follow-up, 42 patients had at least one subsequent 
recurrence or metastasis (7 metastasis only, 33 recurrence only, 2 patients had both). Twenty-nine patients died. On univari-
ate analysis, necrosis (p = 0.002), CNS-G (p = 0.01), and ST-G (p = 0.004) were associated with recurrence-free (RFS) but 
not overall survival (OS). NAB2–STAT6 fusion type was not significantly associated with RFS or OS, but was associated 
with phenotype. A modified ST-G incorporating necrosis showed higher correlation with RFS (p = 0.0006) and remained 
significant (p = 0.02) when considering only the primary tumors. From our data, mitotic rate and necrosis appear to stratify 
this family of tumors most accurately and could be incorporated in a future grading scheme.
Keywords Meningeal hemangiopericytoma · Meningeal solitary fibrous tumor · NAB2–STAT6 · STAT6
Introduction
Meningeal solitary fibrous tumor (SFT)/hemangiopericy-
toma (HPC) is an often aggressive mesenchymal tumor of 
fibroblastic origin that arises from the cranial or spinal dura 
[14]. Although SFT and HPC were initially thought to rep-
resent distinct entities, the identification of NAB2–STAT6 
fusion as a defining molecular alteration in both tumors 
has led to the unification of these entities at both dural and 
extra-dural sites. While the NAB2–STAT6 fusion seems to 
be unique to SFT/HPC, its detection may be difficult unless 
whole-genome sequencing is applied to detect breakpoints 
that occur both in exon and intron boundaries [5, 16]. STAT6 
nuclear expression is accepted as a sensitive surrogate of 
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all fusions, which causes consistent nuclear relocation of 
STAT6 [9, 14, 17]. Tumors arising from the meninges tend 
to exhibit high rates of local recurrence with propensity for 
metastasis outside the central nervous system (CNS), but 
prognostication on histopathology alone has been notori-
ously difficult regardless of site of origin. The current 2016 
WHO CNS grading scheme incorporates phenotype and 
mitotic rate to stratify tumors into three groups (grade 1, 2, 
and 3), while non-meningeal soft-tissue tumors are classified 
by mitotic rate alone into SFT and malignant SFT according 
to the 2013 WHO classification for soft-tissue tumors [10, 
14]. Our earlier work suggested that tumors harboring the 
NAB2 exon 4–STAT6 exon 3 fusion variant exhibited mor-
phologic features similar to the conventional solitary fibrous 
tumor, while there was a trend toward an association with 
the hemangiopericytoma phenotype and more aggressive 
behavior in tumors lacking this variant [11]. We studied a 
large series of patients with SFT/HPC from six tertiary care 
centers, to determine the best grading scheme for menin-
geal-based SFT/HPT and characterize the relationship of 
NAB2–STAT6 fusion status with phenotype and prognosis.
Materials and methods
This study was reviewed and approved by the Institutional 
Review Board at all participating institutions.
Case selection
A cohort of 133 patients with meningeal SFT/HPC (74 
males; 59 females) was identified from six tertiary care cent-
ers. They ranged in age from 17 to 78 years (median 49.2) 
at the initial diagnosis. Tumors were pathologically con-
firmed through review of the first tumor resection (n = 97), 
local recurrence (n = 35), or distant metastasis (n = 1). Data 
regarding treatment and clinical follow-up were obtained at 
the respective institutions based on review of the clinical 
records.
Histologic review
Archived H&E-stained sections were classified phenotypi-
cally as ‘SFT’, ‘HPC’, or tumors with intermediate morpho-
logical features between HPC and SFT (Fig. 1). SFTs were 
low-to-moderate cellular tumors composed of spindled to 
ovoid-shaped cells arranged around branching blood ves-
sels with variable stromal and perivascular hyalinization. 
HPCs harbored ovoid-to-round cells, often in a sheet-like 
growth pattern, with high N:C ratios and scant, amphophilic 
to-clear cytoplasm. Although branching blood vessels were 
typically present, the vasculature of HPC was frequently 
less conspicuous than the conventional SFT, and stromal 
hyalinization was generally absent. Tumors showing the fea-
tures of both SFT and HPC were considered intermediate. 
Mitotic rate was assessed by scanning all available H&E 
slides and counting mitoses (at × 400) in ten consecutive 
fields in the areas of highest mitotic activity. The presence 
of necrosis was recorded for all tumors.
Classification and grading
Tumors were classified and graded according to the most 
recent CNS (2016) (CNS-G) and Soft Tissue (2013) (ST-
G) WHO classification schemes (Fig. 2). According to the 
CNS-G, tumors with a classic SFT histopathological pheno-
type and fewer than five mitoses (× 10 HPF) were considered 
grade 1; tumors with intermediate or HPC phenotype and 
fewer than five mitoses (× 10 HPF) were considered grade 
2; tumors with five or more mitoses (× 10 HPF) were con-
sidered grade 3 irrespective of their histopathological phe-
notype. According to the ST-G, irrespective of their histo-
pathological phenotype, tumors with fewer than five mitoses 
(× 10 HPF) were considered SFT and tumors with five or 
more mitoses (× 10 HPF) were considered malignant SFT.
Immunohistochemistry
A representative tissue block from each tumor was selected 
and stained for STAT6 (Santa Cruz Biotechnology, CA, 
mouse monoclonal antibody, 1:50) and CD34 (Novocastra, 
liquid mouse monoclonal antibody, 1:100). CD34 immuno-
reactivity was recorded as negative (< 5%), focal (5–50%), 
or diffuse (> 50%), while nuclear expression of STAT6 was 
scored as negative (when nuclear STAT6 expression was not 
present in tumor cells) or positive (when the cells showed 
definite STAT6 nuclear expression at least focally in the 
tumor).
Molecular studies
RNA extraction was performed by the Mayo Clinic Pathol-
ogy Research Core using the Qiagen miRNeasy FFPE kit by 
methods previously described by Wang et al. [20]. RT-PCR 
of hypoxanthine phosphoribosyltransferase 1 (HPRT1) was 
used as control for RNA integrity as described previously 
[3, 11] and samples with degraded RNA were discarded to 
avoid generation of false-negative cases. In a first step, we 
screened for the presence of the most common NAB2–STAT6 
fusions exon 4–exon 2, exon 4–exon 3, exon 6–exon 16, and 
exon 6–exon 17 using the well-established single-plex PCR 
with subsequent agarose gel electrophoresis, identifying 
NAB2–STAT6 gene fusions in 52 samples. In a next step, 
samples with good RNA quality but no result in the sin-
gle-plex PCRs were analyzed by next-generation sequenc-
ing using the Archer FusionPlex Sarcoma Kit (ArcherDx, 
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Inc, Boulder, CO, USA) to detect fusions among 26 genes 
employing the Anchored Multiplex PCR-based enrichment, 
identifying NAB2–STAT6 gene fusions in an additional 47 
samples. Briefly, a total of up to 250 ng RNA were used 
as starting material. Library preparation was performed 
according to the manufacturer’s protocol (ArcherDx, Inc) 
and sequencing was done on a NextSeq550 instrument using 
NextSeq500/550 High Output v2 kit (150 cycles) (Illumina, 
Inc., San Diego, CA, USA). The resulting raw data were 
converted to fastq files and were then processed with the 
automated Archer Analysis Bioinformatics Platform (Ver-
sion Archer Analysis 5.1, ArcherDx, Inc).
Statistical methods
Patient and tumor characteristics were summarized with fre-
quencies and percentages or medians, interquartile ranges 
(IQR), or ranges, as appropriate. Fisher’s exact tests were 
used to compare categorical variables between selected 
groups (e.g., CNS-G, ST-G, and molecular cluster type). 
Our correlative analysis was based on the time of surgery, 
which represents when the first tumor was evaluated at the 
Fig. 1  Tumors classified as solitary fibrous tumor contained uniform 
ovoid-to-slightly spindled-shaped cell deposited in a collagenized 
background and arranged around branching and hyalinized blood 
vessels (a), while hemangiopericytomas were highly cellular tumors 
composed of predominantly round cells in a sheet-like pattern (b) 
with less prominent vasculature often showing high mitotic rates (c) 
and necrosis (d)
Fig. 2  CNS (2016) and Soft Tissue (2013) WHO Classification 
schemes
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institution. This was the primary tumor resection for 97 
patients, resection of a recurrent tumor for 35 patients, and 
of a metastasis for 1 patient. This approach was made neces-
sary by the fact that, in 36 patients, the primary tumor was 
not available, and no assumption could be made regarding 
the grade of the primary tumor. A recent study has shown 
histological progression of tumor at recurrence in 16% of 
cases [2]. Recurrence-free survival (RFS) was defined as the 
time between surgery and the first adverse event (local recur-
rence or metastasis) following surgery, censoring patients 
with no adverse event at time of last follow-up. Overall 
survival (OS) was defined as the time between surgery and 
death (any cause), censoring those still alive at last follow-
up. OS and RFS were estimated using the Kaplan–Meier 
method, and were summarized at 5, 10, and 20-year post-
surgery, along with the median survival. OS and RFS were 
compared between selected groups with Cox proportional-
hazard regression models, using the likelihood ratio test 
to assess significance. 95% confidence intervals (CI) were 
also reported for the survival estimates and hazard ratios 
(HR). We also investigated RFS from time of original diag-
nosis to the first adverse event in the patient’s history (this 
also considers the time interval prior to when a recurrent 
sample was evaluated), as well as OS from time of original 
diagnosis. For disease-free survival, deaths due to disease 
were the events, and all non-events (deaths with unknown 
or other causes, along with those still alive) were censored. 
All analyses were performed using SAS version 9.4 (SAS 
Institute Inc, Cary, NC, USA), or R [19]. p values less than 
0.05 were considered statistically significant.
Results
Table 1 summarizes the characteristics of the patient cohort.
Clinical outcome
Follow-up was available in 129 of 133 patients (range 
4 days–22.2 years; median 5 years). At last follow-up, 
104 patients were alive (47 without disease, 24 with dis-
ease, and 33 alive but their disease status was unknown) 
and 29 patients were deceased (20 of disease, 6 of other 
causes, and 3 of unknown cause). The median recur-
rence-free (RFS) and overall survival (OS) times from the 
original diagnosis were 9.6 years and 20.9 years, respec-
tively (Fig. 3). When RFS and OS were calculated from 
the time at which the first surgical specimen was avail-
able for pathology review (indicated as time of surgery), 
the median RFS and OS were 11.3 years and 14.7 years, 
respectively. The differences in RFS and OS with respect 
to time of diagnosis versus time of surgery are explained 
by the influence of the patients in which the first available 
specimen was a recurrence rather than a primary tumor, as 
illustrated in suppl. Figure 1 and suppl. Figure 2 (Online 
Resource 1 and Online Resource 2). When consider-
ing only cases in which the primary tumor was availa-
ble for review, the median RFS for primary tumors was 
12.9 years (79.0% at 5 years) compared to 7.8 years (67.6% 
at 5 years) for recurrent cases (p = 0.14). The median OS 
from the time of surgery for cases in which the primary 
tumor was available for review was 14.7 years (89.1% at 
5 years) compared to 9.6 years (70.3% at 5 years) for those 
in which the recurrence was the first available material 
(p = 0.03). The disease-free survival for all patients at 
5 years was 87.2% (95% CI 80.3, 94.1) and at 10 years 
was 74.2% (95% CI 62.6, 85.7). For patients in which the 
primary tumor was reviewed, the 5- and 10-year survivals 
were 91.5% (95% CI 84.9, 98.1) and 85.5% (95% CI 75.2, 
95.7), respectively, while the 5- and 10-year survivals for 
patients in which a recurrence was reviewed was 85.5% 
(95% CI 75.2, 95.7) and 43.8% (16.3, 71.3), respectively.
Of the entire cohort, 42 patients experienced at least one 
adverse event after surgery (local recurrence or metasta-
sis): 7 patients had metastases only, 33 had local recurrence 
only, and 2 patients had both local recurrence and metastases 
(Table 2). When looking only at the patients from whom the 
primary tumor was reviewed (n = 97), 28 patients experi-
enced either recurrence or metastasis: 4 patients had metas-
tases only, 22 patients had recurrence only, and 2 patients 
had both recurrence and metastases.
Among those in the full cohort who experienced 
an adverse event, the median time from original diag-
nosis to the first local recurrence was 5.6 years (range 
27 days–36.7 years), while the median time to first metas-
tasis was 8.8 years (range 7.1 months–23.4 years). For 
patients from whom the primary tumor was reviewed, 
the median time to first recurrence was 3.5 years (range 
27 days–14.9 years) with median time to first metastasis of 
4.5 years (range 7.1 months–10.3 years).
Histopathology
By histologic criteria, 55 tumors were classified as SFT 
phenotype, 24 as HPC phenotype, and the remaining 54 
were considered intermediate. The median mitotic rate 
was 2 (× 10 HPF) (IQR 1–6; range 0–45 mitoses per 10 
HPF). Necrosis was identified in 16 cases (12%), while 117 
tumors lacked this finding. On univariate analysis, mitotic 
rate (≥ 5 mitoses × 10 HPF) and necrosis were both sig-
nificantly associated with recurrence-free survival (RFS, 
p = 0.004, p = 0.002, respectively) but not overall survival 
(OS, p = 0.12, p = 0.54) (Tables 3, 4). Five- and ten-year RFS 
were 51.1% and 0%, respectively, for tumors with necrosis 
and 80.1% and 56% for those without necrosis (Table 3).
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Table 1  Clinicopathologic features
Total (N = 133)a Specimen type at time of surgery
Primary (N = 97)a Recurrence (N = 35)a Metastasis (N = 1)a
Age at surgery
 Median 54.1 54.1 55.3 41.4
 Range (20.1–87.3) (20.1–83.0) (39.0–87.3) (41.4–41.4)
Age at initial diagnosis
 Median 49.2 52.9 39.3
 Range (17.5–78.8) (20.1–78.8) (17.5–61.1)
Sex
 Female (%) 59 (44.4) 42 (43.3) 17 (48.6) 0
 Male 74 (55.6) 55 (56.7) 18 (51.4) 1
Race/ethnicity
 Caucasian (%) 103 (77.4) 77 (79.4) 26 (74.3) 0
 Hispanic/Latino 6 (4.5) 5 (5.2) 1 (2.9) 0
 African American 9 (6.8) 7 (7.2) 2 (5.7) 0
 Native American 2 (1.5) 0 (0) 2 (5.7) 0
 Asian 3 (2.3) 3 (3.1) 0 (0) 0
 Pacific Islander 2 (1.5) 1 (1.0) 1 (2.9) 0
 Other 2 (1.5) 1 (1.0) 1 (2.9) 0
 Unknown 6 (4.5) 3 (3.1) 2 (5.7) 1
Phenotype
 HPC (%) 24 (18.0) 15 (15.5) 9 (25.7) 0
 INT 54 (40.6) 39 (40.2) 14 (40.0) 1
 SFT 55 (41.4) 43 (44.3) 12 (34.3) 0
Tumor size (cm)
 N 96 75 21 0
 Median 4.1 4.5 3.8
 Q1, Q3 3.3, 6.0 3.1, 6.5 3.3, 5.0
 Range (1.3–11.0) (1.3–11.0) (1.4–6.5)
Mitoses (/10 hpf)
 Median 2.0 1.0 3.0 16.0
 Q1, Q3 1.0, 6.0 1.0, 6.0 1.0, 8.0
 Range (0.0–45.0) (0.0–36.0) (0.0–45.0)
Necrosis
 Absent (%) 117 (88.0) 87 (89.7) 29 (82.9) 1
 Present 16 (12.0) 10 (10.3) 6 (17.1) 0
CNS-G grade
 1 (%) 43 (32.3) 36 (37.1) 7 (20.0) 0
 2 41 (30.8) 28 (28.9) 13 (37.1) 0
 3 49 (36.8) 33 (34.0) 15 (42.9) 1
ST-G grade
 Low (%) 84 (63.2) 64 (66.0) 20 (57.1) 0
 High 49 (36.8) 33 (34.0) 15 (42.9) 1
Extent of resection
 Gross total resection (%) 63 (56.3) 55 (62.5) 8 (33.3) 0
 Subtotal resection 49 (43.8) 33 (37.5) 16 (66.7) 0
CD34
 Negative (< 5) (%) 25 (18.8) 19 (19.6) 6 (17.1) 0
 Focal (5–50) 32 (24.1) 21 (21.6) 10 (28.6) 1
 Diffuse (> 50) 76 (57.1) 57 (58.8) 19 (54.3) 0
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Tumor size
Tumor size was available in 96 patients ranging from 1.3 
to 11.0 cm (Table 1). Tumor size was not significantly 
associated with RFS or OS when considered continuously 
or categorically (tumor size < 5 cm vs tumor size ≥ 5 cm) 
(Tables 3, 4).
Immunohistochemistry
CD34 was recorded as diffuse in the majority of cases 
(n = 76; 57%), while 32 cases (24%) were focally positive 
and 25 were negative (19%). STAT6 immunostain showed 
nuclear expression in 132 (99%) cases. The single case lack-
ing nuclear expression of STAT6 was a T11 spinal mass 
from a 40-year-old woman that recurred multiple times. 
STAT6 immunochemistry was performed on two separate 
specimens from this patient and repeated at two different 
centers (Mayo Clinic and the originating institution), and all 
samples tested were negative. Both specimens of this tumor 
were tested by PCR and showed an NAB2 exon 6–STAT6 
exon 16 fusion.
Grading
Tumors were classified as grade 1 (n = 43), 2 (n = 41), or 3 
(n = 49) using the CNS-G, and SFT (n = 84) or malignant 
SFT (n = 49) using the ST-G scheme (Fig. 2). When com-
paring the extent of CD34 immunostaining among those 
with at least 5% staining, tumors with SFT phenotype were 
Table 1  (continued)
Total (N = 133)a Specimen type at time of surgery
Primary (N = 97)a Recurrence (N = 35)a Metastasis (N = 1)a
Treatment
 Radiation only (%) 60 (53.1) 50 (58.1) 10 (37.0) 0
 Chemotherapy only 1 (0.9) 1 (1.2) 0 (0.0) 0
 Radiation + chemotherapy 3 (2.7) 2 (2.3) 1 (3.7) 0
 No treatment 49 (43.4) 33 (38.4) 16 (59.3) 0
Molecular cluster
 ex2–3_ex18/ex2_ex1–2/other (%) 10 (7.5) 8 (8.2) 2 (5.7) 0
 ex4_ex2–3 29 (21.8) 22 (22.7) 7 (20.0) 0
 ex5–7_ex16–17 60 (45.1) 46 (47.4) 14 (40.0) 0
 No fusion detected 12 (9.0) 8 (8.2) 3 (8.6) 1
 Failed or unavailable 22 (16.5) 13 (13.4) 9 (25.7) 0
a Frequencies not summing to column total indicate missing data. For continuous variables, N is provided in cases of missing data
Fig. 3  Kaplan–Meier plots showing the median recurrence-free sur-
vival (RFS) and overall survival (OS) from the time of the original 
diagnosis, 9.6 years and 20.9 years, respectively. Note that there was 
one death due to disease with unknown date of death and that patient 
is not included in these plots
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more likely to show diffuse CD34 immunoreactivity (88%) 
as compared to tumors with HPC and INT phenotype (35% 
and 63%, respectively), p = 0.0001. Furthermore, CNS-G 1 
tumors were more likely to show diffuse CD34 immunore-
activity (85%) as compared to CNS-G 2 (56%) or 3 (68%), 
p = 0.03.
On univariate analysis, both the CNS-G and ST-G were 
significantly associated with RFS (Table 3, p = 0.014, 0.004, 
respectively) (Fig. 4a, b) but not overall survival (p = 0.23, 
p = 0.12, respectively). Five-year RFS rates were, respec-
tively, 82, 88, and 60%, while 10-year rates were 61, 58, 
and 34% for CNS grades 1, 2, and 3. They were 85 and 60 
at 5 years, and 59 and 34% at 10 years for SFT and malig-
nant SFT, respectively. When considering only the primary 
tumors, ST-G remained significant (p = 0.03), while the 
CNS-G did not (p = 0.07). When evaluating only the recur-
rent cases, the ST-G approached significance (p = 0.05), 
while the CNS-G did not (p = 0.15). Since the ST-G scheme 
appeared to be a simpler way to stratify these tumors, and 
necrosis was associated with decreased RFS on univari-
ate analysis, we attempted to incorporate necrosis into the 
ST-G and stratify tumors into three tiers: (1) tumors with < 5 
mitoses/10 HPF, (2) tumors with ≥ 5 mitoses/10 HPF with-
out necrosis, and (3) tumors with ≥ 5 mitoses/10 HPF with 
necrosis. This modified soft-tissue grading scheme showed a 
strong association with recurrence-free survival (p = 0.0006) 
and remained significant (p = 0.02) when considering only 
the primary tumors and only recurrent tumors (p = 0.04) 
(Fig. 5a–c). Among 84 tumors with < 5 mitoses per 10 HPF, 
necrosis was present only in 3 (3.6%). All three tumors had 
a hemangiopericytomatous-like phenotype. In two patients, 
necrosis was present at the time of primary surgery. One 
of these patients had GTR and one STR. Both received 
radiation therapy. They were both alive without recurrence, 
respectively, at 67 and 38 months. In the third patient, we 
reviewed a recurrent sample, 16 years and 3 months from 
the original diagnosis. Only 1 month postoperative follow-up 
was available in this patient.
NAB2–STAT6 fusion
Molecular analysis was successful in 111 (of 127; 87%) 
cases which could be tested, and NAB2–STAT6 fusion was 
detected in 99 (of 111; 89%) successfully tested tumors: 
NAB2 exon 5–7–STAT6 exon 16–17 (n = 60), NAB2 exon 
4–STAT6 exon 2–3 (n = 29), NAB2 exon 2–STAT6 exon 
1–2 (n = 4), NAB2 exon 2–3–STAT6 exon 18 (n = 4), NAB2 
exon 2–STAT6 exon 5 (n = 1), and NAB2 exon 7–STAT6 
exon 1 (n = 1). The remaining 12 cases lacked an identi-
fiable NAB2–STAT6 fusion. Fusion variants were grouped 
according to their frequency and predicted protein domain 
inclusion into four groups. The four groups based on fusion 
variant included: (1) NAB2 exon 4–STAT6 exon 2–3 (n = 29), 
(2) NAB2 exon 5–7–STAT6 exon 16–17 (n = 60), (3) other 
NAB2–STAT6 fusions (n = 10), and (4) no detectable fusion 
(n = 12). Figure 6 illustrates the relationship between the 
four NAB2–STAT6 fusion groups, and phenotype, mitoses, 
necrosis, CNS-G, ST-G, and modified ST-G.
Fusion cluster and phenotype When comparing fusion 
cluster with phenotype, the majority of NAB2 exon 4–STAT6 
exon 2–3 fusions were seen among tumors with an SFT 
phenotype (n = 24 of 29, 83%), with four cases showing 
intermediate phenotype and one with HPC phenotype. The 
tumors which harbored NAB2 exon 5–7–STAT6 exon 16–17 
were more likely to have an intermediate or HPC pheno-
type (n = 49 of 60 and 82%; n = 34, and n = 15, respectively) 
(p < 0.0001), the remaining 11 (18%) showing an SFT phe-
notype. Among the ten with other fusions, half (5) were 
SFT, four intermediate, and one HPC. Among the 12 with 
no fusion detected, 4 were SFT, 6 intermediate, and 2 HPC.
Fusion cluster and mitotic rate Tumors with NAB2 exon 
4–STAT6 exon 2–3 or “other fusions” were more likely 
to have mitotic rates < 5/10 HPF, whereas tumors with 
NAB2–STAT6 5–7–STAT6 exon 16–17 and without a detect-
able fusion were more likely to have mitotic rates ≥ 5/10 
HPF (p = 0.002).
Fusion cluster and necrosis There was no significant 
association between fusion type or status (absence or pres-
ence of a detected fusion) and necrosis (p = 0.16; p = 0.35, 
respectively).
Fusion cluster and CNS-G There was a statistically sig-
nificant association between type of fusion and CNS-G 
Table 2  Recurrence and metastasis since original diagnosis
a 17 patients had at least one metastasis (five of these patients’ metas-
tasis was in multiple sites). Two of these patients had two metastases 
(brain followed by brain; bone followed by epidural)
N = 133 Patients
Recurrence Metastasis
# Of events per patient
 0 74 116
 1 36 15
 2 13 2
 3+ 10 0
First event after surgery 34 8
Metastasis since diagnosis,  sitea 28 metastases from 17 
patients
 Bone (includes sternum) 7
 Liver 7
 Lung 7
 Brain 2
 Kidney 1
 Pancreas 1
 Other (includes CSF, adnexa, epi-
dural)
3
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(p < 0.0001). The 29 tumors with NAB2 exon 4–STAT6 exon 
2–3 were more frequently grade 1 tumors (n = 21) than grade 
2 or 3 (n = 3, n = 5, respectively). The 60 tumors with NAB2 
exon 5–7–STAT6 exon 16–17 fusion were more frequently 
grade 2 and 3 tumors (n = 22, n = 31, respectively).
Fusion cluster and ST-G There was a statistically sig-
nificant association between type of fusion and ST-G 
(p = 0.002). The 29 tumors harboring NAB2 exon 4–STAT6 
exon 2–3 or the 10 with “other fusions” were more likely 
to be solitary fibrous tumors (n = 24, n = 8) compared to 
Table 3  Recurrence-free survival (RFS)
a NA indicates that the value was not able to be estimated
Variable N Events Median years (95% 
CI)a
5-Year RFS % (95% 
CI)a
10-Year RFS (95% 
CI)a
Hazard ratio (95% CI) p value
Phenotype 0.87
 HPC 24 7 7.8 (5.7–NA) 81.1% (64.2%, 97.9%) 41.7% (8.2%, 75.2%) (Reference)
 INT 54 18 12.9 (8.8–NA) 78.8% (66.3%, 91.3%) 52.7% (34.6%, 70.8%) 0.88 (0.38, 2.30)
 SFT 55 17 11.3 (6.1–NA) 71.3% (57.4%, 85.3%) 53.1% (34.4%, 71.9%) 1.06 (0.45, 2.74)
Mitoses 0.004
 < 5 84 21 14.9 (8.9–NA) 85.0% (76.4%, 93.7%) 58.7% (42.8%, 74.6%) (Reference)
 ≥ 5 49 21 5.7 (3.0–12.9) 59.6% (43.3%, 76.0%) 33.6% (13.9%, 53.2%) 2.48 (1.34, 4.59)
Necrosis 0.002
 Absent 117 33 12.9 (8.2–NA) 80.1% (71.8%, 88.5%) 55.7% (42.5%, 68.9%) (Reference)
 Present 16 9 5.6 (1.5–8.8) 51.1% (25.0%, 77.3%) 0.0% (0.0%, 0.0%) 4.04 (1.76, 8.51)
Tumor size 0.46
 0–5 cm 52 12 78.1% (65.3%, 90.9%) 61.6% (41.9%, 81.4%) –
 ≥ 5 cm 44 18 8.8 (5.6–) 71.3% (56.9%, 85.8%) 46.2% (27.4%, 65.1%) 1.31 (0.64, 2.80)
CNS grade (2016) 0.01
 1 43 11 NA 81.9% (68.6%, 95.1%) 61.0% (40.5%, 81.5%) (Reference)
 2 41 10 14.9 (8.9–NA) 88.2% (77.3%, 99.2%) 58.3% (35.3%, 81.2%) 0.80 (0.33, 1.90)
 3 49 21 5.7 (3.0–12.9) 59.6% (43.3%, 76.0%) 33.6% (13.9%, 53.2%) 2.21 (1.08, 4.78)
Soft-tissue grade (2013) 0.004
 SFT 84 21 14.9 (8.9–NA) 85.0% (76.4%, 93.7%) 58.7% (42.8%, 74.6%) (Reference)
 Malignant SFT 49 21 5.7 (3.0–12.9) 59.6% (43.3%, 76.0%) 33.6% (13.9%, 53.2%) 2.48 (1.34, 4.59)
Modified soft-tissue grade 0.0006
 SFT 84 21 14.9 (8.9–) 85.0% (76.4%, 93.7%) 58.7% (42.8%, 74.6%) (Reference)
 Malignant SFT no 
necrosis
36 12 7.8 (3.3–) 68.1% (49.2%, 87.0%) 46.7% (22.7%, 70.7%) 1.75 (0.83, 3.52)
 Malignant SFT with 
necrosis
13 9 2.0 (1.2–8.8) 42.7% (14.7%, 70.8%) Not estimable* 6.03 (2.53, 13.34)
Resection extent 0.27
 Gross total 63 18 12.9 (8.8–NA) 79.1% (67.4%, 90.8%) 60.0% (42.5%, 77.5%) (Reference)
 Subtotal 49 19 7.8 (5.7–NA) 69.6% (55.7%, 83.5%) 42.6% (23.5%, 61.6%) 1.44 (0.75, 2.77)
Radiation 0.79
 No 50 16 9.2 (7.8–NA) 75.5% (62.1%, 88.8%) 48.9% (27.4%, 70.3%) (Reference)
 Yes 63 20 12.9 (6.1–NA) 78.5% (67.0%, 89.9%) 50.8% (32.2%, 69.3%) 0.91 (0.47, 1.80)
Molecular cluster (most common types) 0.80
 ex4_ex2–3 29 9 11.3 (3.3–NA) 68.2% (48.6%, 87.8%) 59.7% (36.5%, 82.9%) (Reference)
 ex5–7_ex16–17 60 22 8.8 (6.4–NA) 74.0% (61.7%, 86.4%) 42.7% (25.6%, 59.9%) 1.03 (0.49, 2.36)
 No fusion detected 12 4 12.9 (1.3–NA) 90.0% (71.4%, 
100.0%)
72.0% (37.1%, 
100.0%)
0.72 (0.19, 2.26)
Fusion status 0.52
 No fusion detected 12 4 12.9 (1.3–NA) 90.0% (71.4%, 
100.0%)
72.0% (37.1%, 
100.0%)
(Reference)
 Fusion detected (any 
type)
99 33 8.9 (6.9–NA) 73.0% (62.9%, 83.0%) 46.5% (32.2%, 60.7%) 1.39 (0.54, 4.74)
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malignant solitary fibrous tumors (n = 5, n = 2). The 60 
tumors with NAB2 exon 5–7–STAT6 exon 16–17 were malig-
nant SFT in 31 (52%) and SFT in 29 (48%). The majority 
of tumors without a detectable fusion were malignant SFT 
(n = 8) compared to SFT (n = 4).
Fusion cluster and outcome NAB2–STAT6 fusion type 
was not associated with RFS (p = 0.80) or OS (p = 0.29). 
Table 4  Overall survival (OS)
a NA indicates that the value was not able to be estimated
Variable N Events Median years (95% 
CI)a
5-Year OS % (95% 
CI)a
10-Year OS (95% CI)a Hazard ratio (95% CI) p value
Phenotype 0.25
 HPC 24 8 12.7 (4.8–16.8) 73.7% (51.0%, 96.3%) 55.3% (19.7%, 90.8%) (Reference)
 INT 54 13 NA 79.8% (67.8%, 91.8%) 71.8% (56.7%, 87.0%) 0.54 (0.22, 1.38)
 SFT 55 8 14.7 (8.7–) 92.1% (83.6%, 
100.0%)
63.4% (37.2%, 89.5%) 0.44 (0.16, 1.19)
Mitoses 0.12
 < 5 84 16 14.7 (10.6–NA) 90.5% (83.3%, 97.8%) 69.7% (53.6%, 85.7%) (Reference)
 ≥ 5 49 13 13.3 (5.3–NA) 71.1% (55.2%, 87.0%) 66.6% (49.5%, 83.8%) 1.80 (0.85, 3.76)
Necrosis 0.54
 Absent 117 26 14.7 (10.6–NA) 85.2% (77.6%, 92.7%) 68.7% (55.9%, 81.6%) (Reference)
 Present 16 3 NA 72.0% (43.9%, 
100.0%)
72.0% (43.9%, 
100.0%)
1.49 (0.35, 4.38)
Tumor size 0.22
 0–5 cm 52 9 14.7 (–) 79.4% (65.7%, 93.1%) 75.8% (61.0%, 90.6%)
 ≥ 5 cm 44 8 16.8 (10.0–) 95.1% (88.4%, 
100.0%)
71.9% (51.0%, 92.7%) 0.53 (0.19, 1.46)
CNS grade (2016) 0.23
 1 43 6 14.7 (8.7–NA) 93.7% (85.3%, 
100.0%)
67.1% (40.0%, 94.3%) (Reference)
 2 41 10 12.7 (9.6–NA) 87.5% (76.0%, 99.0%) 70.7% (51.1%, 90.4%) 1.47 (0.55, 4.34)
 3 49 13 13.3 (5.3–NA) 71.1% (55.2%, 87.0%) 66.6% (49.5%, 83.8%) 2.26 (0.89, 6.45)
Soft-tissue grade (2013) 0.12
 SFT 84 16 14.7 (10.6–NA) 90.5% (83.3%, 97.8%) 69.7% (53.6%, 85.7%) (Reference)
 Malignant SFT 49 13 13.3 (5.3–NA) 71.1% (55.2%, 87.0%) 66.6% (49.5%, 83.8%) 1.80 (0.85, 3.76)
Modified soft-tissue grade 0.29
 SFT 84 16 14.7 (10.6–) 90.5% (83.3%, 97.8%) 69.7% (53.6%, 85.7%) (Reference)
 Malignant SFT no 
necrosis
36 10 13.3 (4.8–) 72.7% (54.5%, 90.9%) 66.7% (46.5%, 86.8%) 1.73 (0.75, 3.79)
 Malignant SFT with 
necrosis
13 3 67.3% (35.6%, 99.0%) 67.3% (35.6%, 99.0%) 2.10 (0.48, 6.43)
Resection extent 0.05
 Gross total 63 8 16.8 (12.7–NA) 93.0% (85.4%, 
100.0%)
77.2% (59.3%, 95.1%) (Reference)
 Subtotal 49 14 13.3 (7.5–NA) 76.8% (63.3%, 90.4%) 62.8% (44.3%, 81.3%) 2.33 (0.996, 5.86)
Radiation 0.30
 No 50 11 12.7 (10.0–NA) 87.2% (76.6%, 97.8%) 63.8% (41.1%, 86.6%) (Reference)
 Yes 63 10 16.8 (13.3–NA) 86.5% (76.3%, 96.6%) 76.0% (59.6%, 92.3%) 0.64 (0.26, 1.52)
Molecular cluster (most common types) 0.29
 ex4_ex2–3 29 6 12.7 (8.7–NA) 81.5% (65.0%, 97.9%) 65.2% (33.7%, 96.6%) (Reference)
 ex5–7_ex16–17 60 11 NA 87.0% (77.1%, 96.9%) 74.9% (59.6%, 90.2%) 0.80 (0.30, 2.32)
 No fusion detected 12 7 10.0 (1.6–NA) 61.9% (32.1%, 91.7%) 41.3% (10.6%, 71.9%) 1.79 (0.58, 5.68)
Fusion status 0.13
 No fusion detected 12 7 10.0 (1.6–NA) 61.9% (32.1%, 91.7%) 41.3% (10.6%, 71.9%) (Reference)
 Fusion detected (any 
type)
99 18 14.3 (12.7–NA) 84.9% (76.6%, 93.2%) 73.3% (60.5%, 86.2%) 0.48 (0.20, 1.25)
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Fig. 4  Univariate analysis shows that both the CNS-G (a) and ST-G (b) are significantly associated with recurrence-free survival (Table  3, 
p = 0.01, 0.004, respectively) but not overall survival (p = 0.23, p = 0.12, respectively)
Fig. 5  Modified soft-tissue 
grading scheme showed strong 
association with recurrence-
free survival (p = 0.0006) and 
remained significant (p = 0.02) 
when considering only the pri-
mary tumors and only recurrent 
tumors (p = 0.04) (a–c)
Fig. 6  This graph highlights the 
relationship between the four 
NAB2–STAT6 fusion groups, 
and phenotype, mitoses, necro-
sis, CNS-G, ST-G, and modified 
ST-G
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Furthermore, when comparing tumors with and without 
identifiable NAB2–STAT6 fusions (dichotomously), there 
was no significant difference in recurrence-free survival 
(p = 0.52) or overall survival (p = 0.13).
Treatment data
Sixty-three patients (56.3%) underwent gross total resec-
tion, while the tumor was subtotally resected in 49 patients 
(43.8%). In the remaining 21 patients, the extent of surgical 
resection was unknown. Sixty patients (53.1%) received only 
adjuvant radiation therapy, a single patient (1%) was treated 
with chemotherapy alone, 3 patients (2.7%) underwent both 
adjuvant radiation and chemotherapy, and the remaining 49 
patients (43.4%) were treated with surgery alone. Neither 
extent of resection nor adjuvant radiation therapy was signif-
icantly associated with outcome (overall survival: p = 0.051, 
0.30; recurrence-free survival: p = 0.27, 0.79, respectively).
Discussion
Our study confirms the natural history of meningeal-based 
SFT/HPC, showing high rates of local recurrence and distant 
metastasis. Furthermore, patients in our cohort demonstrate 
a tendency for late adverse events, a subset developing their 
first recurrences/metastasis over 3 decades after the initial 
diagnosis. Similarly, patients continue to die of disease 
almost 40 years after the initial diagnosis. In a subset of our 
cases, only material from recurrence (not the primary tumor) 
was available for review. As these patients are at greater risk 
for adverse events, as shown by our data, these cases influ-
ence the OS and RFS of the entire cohort. However, trends 
for overall survival and RFS of both primary and recurrent 
cases remain similar.
On univariate analysis, mitotic rate and necrosis were 
each significantly associated with RFS but not OS. Since 
the CNS-G and ST-G schemes take mitotic rate into account, 
it is not surprising that both appear to show association with 
RFS. However, there does not appear to be a significant dif-
ference between grade 1 and grade 2 according to CNS-G, 
and the ST-G scheme, based solely on mitotic rate, appears 
to stratify tumors in a simpler and more efficient fashion. 
Furthermore, the ST-G maintains statistical significance 
when looking only at primary cases. A recent risk stratifica-
tion model proposed by Demicco et al. for non-meningeal 
tumors incorporates mitotic rate and necrosis, along with 
patient age and tumor size, and appears to show prognostic 
significance in determining propensity for metastatic disease 
[8]. The class sizes used in soft tissue with cut-offs of 5, 10, 
and 15 cm would not be easily applicable to intracranial 
tumors, which grow in a confined space. However, necrosis 
was associated with decreased RFS on univariate analysis in 
our series. Furthermore, incorporating necrosis into ST-G, 
i.e., classifying tumors based on mitotic rate and necrosis, 
seems to improve the outcome models when compared to 
mitotic rate alone. In their recent work from 2018, Macagno 
et al. sought to validate an updated version of the Marseille 
Grading Scheme which segregated 132 tumors into three 
groups based on mitotic activity (≥ 5 mitotic figures/10 
HPF) and necrosis [4, 15]. On univariate analysis, they 
found that extent of surgery, radiotherapy/chemotherapy, 
and mitotic rate were significant in predicting RFS, while 
radiation, mitotic rate, and necrosis were significant for 
disease-specific survival [15]. Extent of surgery and mitotic 
rate remained significant prognostic factors for RFS with 
multivariate analysis, while necrosis and radiotherapy were 
significant for disease-specific survival [15]. Our data paral-
lel these findings, confirming that a grading scheme incor-
porating mitotic rate and necrosis best stratifies SFT/HPC, 
and the combination of high mitotic activity and necrosis 
portends poor prognosis for this entity. If these findings 
are corroborated by additional studies, this grading scheme 
could be utilized to guide treatment decisions regarding 
adjuvant therapy (e.g., radiotherapy) after surgery. Of note 
is the fact that, once necrosis is added to the ST-G model, 
the RFS curve of SFT does not appear to be significantly dif-
ferent from that of malignant SFT without necrosis, which, 
however, remains distinctly separate and inferior. Concern 
could be raised about applying the term malignant SFT as 
per the 2013 WHO classification for soft-tissue tumors to 
these tumors. Larger studies and longer follow-up are needed 
to answer this question.
In 2014, Barthelmess et al. examined a series of non-
meningeal SFT/HPC and showed that tumors harboring 
NAB2 exon 4–STAT6 exon 2/3 fusions had lower recurrence 
rates than those with NAB2 exon 6–STAT6 exon 16/17 or 
other fusions [3]. Similarly, our subsequent work with 
meningeal-based lesions suggested a trend toward more 
aggressive behavior in tumors lacking NAB2 exon 4–STAT6 
exon 3. Even though additional studies of dural- and non-
dural-based solitary fibrous tumors have shown consistent 
association between mitotic rate and fusion variant, with 
tumors harboring NAB2 exon 4–STAT6 exon 2/3 fusions 
consistently exhibiting lower mitotic rates than those with 
NAB2 exon 6–STAT6 exon 16/17, no further relationship 
between fusion variant and disease-free survival has been 
reported [1, 3, 6, 12, 18, 21]. Our current study that focused 
specifically on a large cohort of meningeal-based tumors 
from multiple large tertiary care centers provides further 
support that fusion status fails to associate with RFS or over-
all survival.
Interestingly, several studies, including our earlier work, 
have suggested that fusion type appears to be associated 
with phenotype. The NAB2 exon 4–STAT6 exon 2–3 vari-
ant seems to be most often found in tumors resembling the 
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conventional ‘solitary fibrous tumor,’ while tumors with 
NAB2 exon 6–STAT6 exon 16–17 exhibit morphologic 
features consistent with what was previously considered 
‘hemangiopericytoma’ [1, 3, 11]. Our current findings are 
concordant with these prior reports and suggest that tumor 
phenotype is related to fusion variant.
The sensitivity of STAT6 for the diagnosis of solitary 
fibrous tumors has been reported to range from 86 to 98% 
in large series at both CNS and soft-tissue sites [7, 9, 13, 
17]. We identified only a single case of SFT/HPC which 
harbored an NAB2 exon 6–STAT6 exon 16 fusion but lacked 
nuclear STAT6 immunoreactivity. The tissue blocks from 
this patient were from 1997 and 1998, and it is possible 
that the age of the blocks precluded accurate immunohisto-
chemical analysis. We also considered the possibility that 
the epitope recognized by our antibody may be lost in this 
specific fusion. However, the fusion in this case is the most 
frequently recognized, and, consequently, we would not 
expect loss of STAT6 staining based on fusion type. Regard-
less, the absence of STAT6 immunostaining in a tumor with 
morphologic features consistent with SFT/HPC should lead 
to the consideration of molecular testing to assess for the 
presence of NAB2–STAT6 fusion.
In conclusion, meningeal SFT/HPC is an aggressive 
tumor with propensity for high rates of recurrence and 
metastasis, which sometimes occur decades after the ini-
tial diagnosis. A grading scheme incorporating mitotic rate 
and necrosis seems to stratify this family of tumors most 
accurately. Although fusion type does not appear to relate to 
outcome in dural-based lesions, it does seem to be associated 
with tumor phenotype.
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